Biological treatments for severe asthma

키워드

참고문헌 (50)

1. Moore WC, "Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute’s Severe Asthma Research Program", J Allergy Clin Immunol, 119, pp.405~413 (2007)
2. Chung KF, "International ERS", ATS guidelines on definition, evaluation and treatment of severe asthma, 2014, pp.43, 343~373
3. Eun-young Lee, "Increasing Prevalence and Mortality of Asthma With Age in Korea, 2002–2015: A Nationwide, Population-Based Study", Allergy, Asthma & Immunology Research, 12(3), pp.467~484 (2020), 대한천식알레르기학회
4. 김상헌, "Perceptions of Severe Asthma and Asthma-COPD Overlap Syndrome Among Specialists: A Questionnaire Survey", Allergy, Asthma & Immunology Research, 10(3), pp.225~235 (2018), 대한천식알레르기학회
5. Ivanova JI, "Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma", J Allergy Clin Immunol, 129, pp.1229~1235 (2012)
6. 김주희, "중증천식의 진단", 대한내과학회지, 93(2), pp.153~158 (2018), 대한내과학회
7. Wenzel SE, "Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics", Am J Respir Crit Care Med, 160, pp.1001~1008 (1999)
8. Schleich F, "Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR)", Respir Med, 108, pp.1723~1732 (2014)
9. Pearce N, "How much asthma is really attributable to atopy?", Thorax, 54, pp.268~272 (1999)
10. Russell RJ, "Pathogenesis of asthma: implications for precision medicine", Clin Sci (Lond), 131, pp.1723~1735 (2017)
11. Diver S, "New and emerging drug treatments for severe asthma", Clin Exp Allergy, 48, pp.241~252 (2018)
12. McGregor MC, "Role of biologics in asthma", Am J Respir Crit Care Med, 199, pp.433~445 (2019)
13. Pavord ID, "The current and future role of biomarkers in type 2 cytokine-mediated asthma management", Clin Exp Allergy, 47, pp.148~160 (2017)
14. Bullens DM, "IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx?", Respir Res, 7, pp.135~ (2006)
15. Green RH, "Analysis of induced sputum in adults with asthma : identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids", Thorax, 57, pp.875~879 (2002)
16. Choy DF, "TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma", Sci Transl Med, 7 (2015)
17. Godar M, "Personalized medicine with biologics for severe type 2 asthma : current status and future prospects", MAbs, 10, pp.34~45 (2018)
18. Gibson PG, "Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial", Lancet, 390, pp.659~668 (2017)
19. Busse WW, "Biological treatments for severe asthma : a major advance in asthma care", Allergol Int, 68, pp.158~166 (2019)
20. Strunk RC, "Omalizumab for asthma", N Engl J Med, 354, pp.2689~2695 (2006)
21. Busse W, "Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma", J Allergy Clin Immunol, 108, pp.184~190 (2001)
22. Solèr M, "The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics", Eur Respir J, 18, pp.254~261 (2001)
23. Hanania NA, "Omalizumab in severe allergic asthma inadequately controlled with standard therapy : a randomized trial", Ann Intern Med, 154, pp.573~582 (2011)
24. Pillai P, "Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopic asthma", Eur Respir J, 48, pp.1593~1601 (2016)
25. Humbert M, "Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy(GINA 2002 step 4 treatment) : INNOVATE", Allergy, 60, pp.309~316 (2005)
26. Hanania NA, "Exploring the effects of omalizumab in allergic asthma : an analysis of biomarkers in the EXTRA study", Am J Respir Crit Care Med, 187, pp.804~811 (2013)
27. Bousquet J, "Persistency of response to omalizumab therapy in severe allergic(IgE-mediated)asthma", Allergy, 66, pp.671~678 (2011)
28. Byung-Keun Kim, "Evaluation and Management of Difficult-to-Treat and Severe Asthma: An Expert Opinion From the Korean Academy of Asthma, Allergy and Clinical Immunology, the Working Group on Severe Asthma", Allergy, Asthma & Immunology Research, 12(6), pp.910~933 (2020), 대한천식알레르기학회[DOI]
29. Cox L, "American Academy of Allergy, Asthma & Immunology", American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report, 2011, pp.128, 210~212
30. Walsh GM, "An update on biologic-based therapy in asthma", Immunotherapy, 5, pp.1255~1264 (2013)
31. Chupp GL, "Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial", Lancet Respir Med, 5, pp.390~400 (2017)
32. Ortega HG, "Mepolizumab treatment in patients with severe eosinophilic asthma", N Engl J Med, 371, pp.1198~1207 (2014)
33. Pavord ID, "Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial", Lancet, 380, pp.651~659 (2012)
34. Bel EH, "Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma", N Engl J Med, 371, pp.1189~1197 (2014)
35. Katial RK, "Changing paradigms in the treatment of severe asthma : the role of biologic therapies", J Allergy Clin Immunol Pract, 5(2 Suppl), pp.S1~S14 (2017)
36. Bjermer L, "Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels : a randomized phase 3 study", Chest, 150, pp.789~798 (2016)
37. Castro M, "Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study", Am J Respir Crit Care Med, 184, pp.1125~1132 (2011)
38. Castro M, "Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials", Lancet Respir Med, 3, pp.355~366 (2015)
39. Murphy K, "Long-term safety and efficacy of reslizumab in patients with eosinophilic asthma", J Allergy Clin Immunol Pract, 5, pp.1572~1581 (2017)
40. Bleecker ER, "Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial", Lancet, 388, pp.2115~2127 (2016)
41. 박해심, "Efficacy and Safety of Benralizumab for Korean Patients With Severe, Uncontrolled Eosinophilic Asthma", Allergy, Asthma & Immunology Research, 11(4), pp.508~518 (2019), 대한천식알레르기학회
42. Nair P, "Oral glucocorticoid-sparing effect of benralizumab in severe asthma", N Engl J Med, 376, pp.2448~2458 (2017)
43. FitzGerald JM, "Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial", Lancet, 388, pp.2128~2141 (2016)
44. Busse WW, "Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial", Lancet Respir Med, 7, pp.46~59 (2019)
45. Pepper AN, "Biologic therapy and novel molecular targets of severe asthma", J Allergy Clin Immunol Pract, 5, pp.909~916 (2017)
46. Castro M, "Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma", N Engl J Med, 378, pp.2486~2496 (2018)
47. Rabe KF, "Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma", N Engl J Med, 378, pp.2475~2485 (2018)
48. Wenzel S, "Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist : a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial", Lancet, 388, pp.31~44 (2016)
49. Papaioannou AI, "Towards precision medicine in severe asthma : treatment algorithms based on treatable traits", Respir Med, 142, pp.15~22 (2018)
50. Fitzpatrick AM, "Severe asthma phenotypes - how should they guide evaluation and treatment?", J Allergy Clin Immunol Pract, 5, pp.901~908 (2017)

관련 논문AI추천